ALVO OAKTREE ACQUISITION CORP II

Main Results of 2025 Annual and Extraordinary General Meeting

Main Results of 2025 Annual and Extraordinary General Meeting

REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. 

All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at:

/corporate-governance/annual-general-meeting-2025

Alvotech Investor Relations

Benedikt Stefansson



EN
25/06/2025

Underlying

ALVOOAKTREE ACQUISITION CORP II

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OAKTREE ACQUISITION CORP II

 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Main Results of 2025 Annual and Extraordinary General Meeting

Main Results of 2025 Annual and Extraordinary General Meeting The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: Alvotech Investor Relations Benedikt Stefansson

9h / 51m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Niðurstaða aðalfundar Alvotech árið 2025

Niðurstaða aðalfundar Alvotech árið 2025 Aðalfundur Alvotech S.A. („félagsins“) fór fram 25. júní 2025. Fundurinn var haldinn í Lúxemborg, á skrifstofu lögfræðistofunnar Arendt við Avenue John F. Kennedy 41A.   Allar tillögur á dagskrá fundarins voru samþykktar. Ítarleg fundargerð og niðurstöður atkvæðagreiðslu verða birtar á vef félagins á sérstöku svæði fyrir gögn aðalfundarins: Fjárfestatengsl AlvotechBenedikt Stefánsson, forstöðumaður Viðhengi

9h / 51m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Main Results of 2025 Annual and Extraordinary General Meeting

Main Results of 2025 Annual and Extraordinary General Meeting REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.  All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company’s special web portal for the 2025 Annual General Meeting at: /corporate-governance/annual-general-m...

9h / 51m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Positive Top Line Results from Confirmatory Efficacy Study for Propose...

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and r...

22h / 36m 1 EN
 PRESS RELEASE
Free
ALVO OAKTREE ACQUISI...

Jákvæð niðurstaða úr klínískri rannsókn fyrir fyrirhugaða hliðstæðu Al...

Jákvæð niðurstaða úr klínískri rannsókn fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair Alvotech (NASDAQ: ALVO) og samstarfsaðilar félagsins, Kashiv Biosciences og Advanz Pharma, kynntu í dag að jákvæð niðurstaða hefði náðst í klínískri rannsókn sem bar saman virkni AVT23, fyrirhugaðrar hliðstæðu líftæknilyfsins Xolair (omalizumab), og virkni frumlyfsins. Xolair er lyf sem gefið er við ofnæmisastma og fleiri skyldum sjúkdómum. Kashiv Biosciences er líftæknifyrirtæki með höfuðstöðvar í New Jersey í Bandaríkjunum. Advanz Pharma er alþjóðlegt lyfjafyrirtæki sem markaðssetur lyfse...

22h / 36m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch